Samuel Kim, MD
Rheumatology · Lawrenceville, GANPI 1629386388
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,304 of the $23,733 with a category attached, or 89.8%. 38 manufacturers reported payments, led by Amgen at 27.2% of the total.
Across 1,215 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- AbbVie$4K
- Johnson & Johnson$2K
- Novartis$2K
- UCB, Inc.$1K
- AstraZeneca$918
- plus $7K from 32 others
What the payments were for
- Speaking & faculty fees$2,2509%
- Travel & lodging$190%
- Food & beverage$21,30490%
- Education$1601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 279 | $6,460 |
| AbbVie | 208 | $4,199 |
| Johnson & Johnson(2 entities) | 117 | $2,389 |
| Novartis | 116 | $1,708 |
| UCB, Inc. | 77 | $1,411 |
| AstraZeneca(2 entities) | 39 | $918 |
| GSK | 52 | $900 |
| E.r. Squibb & Sons, L.L.C. | 50 | $809 |
| Radius Health, Inc. | 47 | $758 |
| Lilly USA, LLC | 33 | $606 |
| Pfizer | 34 | $580 |
| Mallinckrodt Hospital Products Inc. | 25 | $499 |
| Genentech USA, Inc. | 27 | $434 |
| Boehringer Ingelheim | 18 | $336 |
| Sobi, Inc | 15 | $275 |
| Sanofi | 13 | $267 |
| Aurinia Pharma U.S., Inc. | 11 | $220 |
| Pacira Therapeutics, Inc. | 9 | $195 |
| Organon | 8 | $105 |
| Mallinckrodt Enterprises LLC | 6 | $99 |
| Invivyd Inc | 3 | $90 |
| ANI Pharmaceuticals, Inc. | 3 | $63 |
| Novo Nordisk | 4 | $61 |
| Assertio Therapeutics, Inc. | 4 | $50 |
| CSL Behring | 2 | $50 |
| Hikma Pharmaceuticals USA | 3 | $41 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Sandoz | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Zimmer Biomet | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,733 in reported general payments places this provider in the 85th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 11 | $82,108 |
| BenlystaBelimumab | 11 | $60,784 |
| RemicadeInfliximab | 12 | $58,292 |
| ProliaDenosumab | 27 | $46,762 |
| TymlosAbaloparatide | 11 | $42,259 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 14 | $33,431 |
| Pilocarpine Hcl | 23 | $2,649 |
| Mycophenolate Mofetil | 13 | $1,993 |
| Hydroxychloroquine Sulfate | 28 | $1,311 |
| MethotrexateMethotrexate Sodium | 61 | $1,167 |
| Tizanidine Hcl | 93 | $853 |
| Prednisone | 119 | $700 |
| Gabapentin | 29 | $520 |
| Duloxetine Hcl | 17 | $412 |
| Pregabalin | 13 | $358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia, Evenity (2 Syringes) | $6,460 | $80,19341 claims |
| GSKBenlysta | $900 | $60,78411 claims |
| Johnson & JohnsonRemicade | $2,389 | $58,29212 claims |
| Radius Health, Inc.Tymlos | $758 | $42,25911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Lawrenceville
- Theresa Lawrence FordLawrenceville$410K
- Cynthia ElliottLawrenceville$84K
- Glenn ParrisLawrenceville$45K
- Madhurika SamakurLawrenceville$23K
- Byung BanLawrenceville$19K
- Zohair AhmedLawrenceville$15K
- James MossellTifton$1.6M
- Gary MyersonAtlanta$1M
- William WilsonAtlanta$344K
- Jefrey LiebermanDecatur$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.